Prevalence of Type III Secretion Protein Exoenzymes and Antimicrobial Susceptibility Patterns from Bloodstream Isolates of Patients with Pseudomonas aeruginosa Bacteremia

被引:41
作者
Garey, K. W. [1 ,2 ]
Vo, Q. P. [1 ]
Larocco, M. T. [2 ]
Gentry, L. O. [2 ]
Tam, V. H. [1 ,2 ]
机构
[1] Univ Houston, Coll Pharm, Dept Clin Sci & Adm, Houston, TX 77030 USA
[2] St Lukes Episcopal Hosp, Houston, TX 77030 USA
关键词
Pseudomonas aeruginosa; type III secretion proteins; bacteremia; antibiotic susceptibility; epidemiology;
D O I
10.1179/joc.2008.20.6.714
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to determine the prevalence of two type III secretion effector proteins, exoU and exoS from bloodstream isolates of hospitalized patients with Pseudomonas aeruginosa (PSA) bacteremia, to characterize antimicrobial susceptibility patterns, and to compare mortality rates. PSA bloodstream isolates and antibiotic susceptibility profiles were collected from a university-affiliated hospital. ExoS and exoU genes were detected by polymerase chain reaction. Hospital mortality was assessed by medical chart review. 119 of 122 (97.5%) PSA bloodstream isolates contained either the exoS or exoU genes. ExoS was the most prevalent (n=86; 70.5%) followed by exoU (n=31; 25.4%), both genes (n=2; 1.6%) or neither gene (n=3; 2.5%). Isolates containing the exoU gene were significantly more likely to be resistant to cefepime, ceftazidime, piperacillin-tazobactam, carbapenems, fluoroquinolones, and gentamicin (p<0.05 for all). Mortality was high in patients with PSA bacteremia and did not differ among patients infected with the exoS isolates (n=3 7; 43%) or exoU isolates (n=11; 35%). One of two type III secretion effector proteins were almost universally present in PSA bloodstream isolates. Isolates containing the exoU gene were more likely to be resistant to multiple antibiotics..
引用
收藏
页码:714 / 720
页数:7
相关论文
共 35 条
[31]   Role of the type III secreted exoenzymes S, T, and Y in systemic spread of pseudomonas aeruginosa PAO1 in vivo [J].
Vance, RE ;
Rietsch, A ;
Mekalanos, JJ .
INFECTION AND IMMUNITY, 2005, 73 (03) :1706-1713
[32]   Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment [J].
Vidal, F ;
Mensa, J ;
Almela, M ;
Martinez, JA ;
Marco, F ;
Casals, C ;
Gatell, JM ;
Soriano, E ;
deAnta, MTJ .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (18) :2121-2126
[33]   ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system [J].
Yahr, TL ;
Vallis, AJ ;
Hancock, MK ;
Barbieri, JT ;
Frank, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (23) :13899-13904
[34]   Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon [J].
Yahr, TL ;
MendeMueller, LM ;
Friese, MB ;
Frank, DW .
JOURNAL OF BACTERIOLOGY, 1997, 179 (22) :7165-7168
[35]   Type III secretion system-associated toxins, proteases, serotypes, and antibiotic resistance of pseudomonas aeruginosa isolates associated with keratitis [J].
Zhu, H ;
Conibear, TCR ;
Bandara, R ;
Aliwarga, Y ;
Stapleton, F ;
Willcox, MDP .
CURRENT EYE RESEARCH, 2006, 31 (04) :297-306